Regulus Therapeutics Announces Participation at Upcoming Healthcare Investment ConferencesPRNewsWire • 11/26/24
Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent UpdatesPRNewsWire • 11/07/24
Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)PRNewsWire • 10/08/24
Regulus Therapeutics Announces Participation at Two Healthcare Investment ConferencesPRNewsWire • 08/28/24
Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent UpdatesPRNewsWire • 08/08/24
Regulus Therapeutics to Present at the Canaccord Genuity 44th Annual Growth ConferencePRNewsWire • 08/06/24
Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)PRNewsWire • 06/24/24
Regulus Therapeutics Announces Expected Addition to the Russell 3000® and Russell 2000® IndexesPRNewsWire • 06/04/24
Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical OfficerPRNewsWire • 05/16/24
Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent UpdatesPRNewsWire • 05/09/24
Regulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)PRNewsWire • 05/06/24
Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast SeriesPRNewsWire • 04/30/24
Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent UpdatesPRNewsWire • 03/21/24
Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of EquityPRNewsWire • 03/12/24
Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)PRNewsWire • 03/12/24
Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)PRNewsWire • 01/02/24
Regulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx ConferencePRNewsWire • 11/22/23
Regulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent UpdatesPRNewsWire • 11/09/23
Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)PRNewsWire • 11/02/23
Regulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)PRNewsWire • 10/19/23
Regulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)PRNewsWire • 09/20/23
Regulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)PRNewsWire • 09/13/23